Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Marc Classe

Showing results (51-60 of 108) with videos related to

Pageof 11
Sort By:
Human Reproduction (Oxford, England)|April 9, 2005
Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d'Oncologie Gynécologique)Philippe Morice, Eric Leblanc, Annie Rey, et al.
Cancers|August 10, 2024
Omission of Completion Axillary Lymph Node Dissection for Patients with Breast Cancer Treated by Upfront Mastectomy and Sentinel Node Isolated Tumor Cells or MicrometastasesGilles Houvenaeghel, Mellie Heinemann, Jean-Marc Classe, et al.
Bulletin Du Cancer|February 25, 2020
[Current advances in immunotherapy in ovarian cancer]Olivia Le Saux, Bertrand Dubois, Marc-Henri Stern, et al.
Bulletin Du Cancer|December 21, 2019
[Retrospective study: Late surgery post chemotherapy versus after 3-4 cures in treatment of advanced ovarian cancer]Quiterie de Fréminville, Idlir Licaj, Jean-Sebastien Frenel, et al.
Bulletin Du Cancer|December 27, 2021
Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancerPatricia Pautier, Thibault de la Motte-Rouge, Fabrice Lécuru, et al.
Annals of Surgical Oncology|May 14, 2014
Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control studyJean-François Le Brun, Loic Campion, Dominique Berton-Rigaud, et al.
Breast Cancer Research and Treatment|May 6, 2025
How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?Clémentine Jankowski, Gilles Houvenaeghel, Celine Renaudeau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2008
Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal originDominique Elias, Jérémie H Lefevre, Julie Chevalier, et al.
Plos One|August 11, 2011
NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartmentNassima Redjimi, Karine Duperrier-Amouriaux, Isabelle Raimbaud, et al.
Bulletin Du Cancer|December 15, 2015
[Perception of pT1a,b pN0 breast tumor prognosis by the French oncology community: Results of the EURISTIC national survey]Marc Spielmann, Florence Dalenc, Yoann Pointreau, et al.
Pageof 11

Showing results (51-60 of 108) with videos related to

Sort By:
Pageof 11
Human Reproduction (Oxford, England)|April 9, 2005
Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d'Oncologie Gynécologique)Philippe Morice, Eric Leblanc, Annie Rey, et al.
Cancers|August 10, 2024
Omission of Completion Axillary Lymph Node Dissection for Patients with Breast Cancer Treated by Upfront Mastectomy and Sentinel Node Isolated Tumor Cells or MicrometastasesGilles Houvenaeghel, Mellie Heinemann, Jean-Marc Classe, et al.
Bulletin Du Cancer|February 25, 2020
[Current advances in immunotherapy in ovarian cancer]Olivia Le Saux, Bertrand Dubois, Marc-Henri Stern, et al.
Bulletin Du Cancer|December 21, 2019
[Retrospective study: Late surgery post chemotherapy versus after 3-4 cures in treatment of advanced ovarian cancer]Quiterie de Fréminville, Idlir Licaj, Jean-Sebastien Frenel, et al.
Bulletin Du Cancer|December 27, 2021
Prise en charge médicale de la récidive du cancer épithélial de l'ovaire: Medical management of recurrent epithelial ovarian cancerPatricia Pautier, Thibault de la Motte-Rouge, Fabrice Lécuru, et al.
Annals of Surgical Oncology|May 14, 2014
Survival benefit of hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer: a multi-institutional case control studyJean-François Le Brun, Loic Campion, Dominique Berton-Rigaud, et al.
Breast Cancer Research and Treatment|May 6, 2025
How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?Clémentine Jankowski, Gilles Houvenaeghel, Celine Renaudeau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 24, 2008
Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal originDominique Elias, Jérémie H Lefevre, Julie Chevalier, et al.
Plos One|August 11, 2011
NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartmentNassima Redjimi, Karine Duperrier-Amouriaux, Isabelle Raimbaud, et al.
Bulletin Du Cancer|December 15, 2015
[Perception of pT1a,b pN0 breast tumor prognosis by the French oncology community: Results of the EURISTIC national survey]Marc Spielmann, Florence Dalenc, Yoann Pointreau, et al.
Pageof 11